Y534 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â À幫±äÀ强 ¾àÁ¦ | Intestinal atonia drugs causing adverse effects in therapeutic use |
 |
Y535 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¼ÒÈÁ¦ | Digestants causing adverse effects in therapeutic use |
 |
Y536 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Áö»çÁ¦ | Antidiarrheal drugs causing adverse effects in therapeutic use |
 |
Y537 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸ÅäÁ¦ | Emetics causing adverse effects in therapeutic use |
 |
Y538 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î À§Àå°èÅë¿¡ ÀÛ¿ëÇÏ´Â ±âŸ Á¦Á¦ | Other agents primarily affecting the gastrointestinal system causing adverse effects in therapeutic use |
 |
Y539 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ÀÏÂ÷ÀûÀ¸·Î À§Àå°èÅë¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents primarily affecting the gastrointestinal system, unspecified causing adverse effects in therapeutic use |
 |
Y54 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ¼öºÐÆòÇü°ú ¹«±â¹° ¹× ¿ä»ê ´ë»ç¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents primarily affecting water-balance and mineral and uric acid metabolism causing adverse effects in therapeutic use |
 |
Y540 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¤ÁúÄÚÆ¼ÄÚÀ̵å | Mineralocorticoid causing adverse effects in therapeutic use |
 |
Y541 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¤ÁúÄÚÆ¼ÄÚÀÌµå ±æÇ×Á¦[¾Ëµµ½ºÅ׷бæÇ×Á¦] | Mineralocorticoid antagonists [aldosterone antagonists] causing adverse effects in therapeutic use |
 |
Y542 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ź»ê¾ÈÈ÷µå¶ó¾ïÁ¦Á¦ | Carbonic-anhydrase inhibitors causing adverse effects in therapeutic use |
 |
Y542 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾Æ¼¼Å¸Á¹¾Æ¹Ìµå | Acetazolamide causing adverse effects in therapeutic use |
 |
Y543 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â º¥Á¶Æ¼¾Æµð¾ÆÁø À¯µµÃ¼ | Benzothiadiazine derivatives causing adverse effects in therapeutic use |
 |
Y544 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â [°í¸®]ÀÌ´¢Á¦ | Loop [High-ceiling] diuretics causing adverse effects in therapeutic use |
 |
Y545 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ÀÌ´¢Á¦ | Other diuretics causing adverse effects in therapeutic use |
 |
Y546 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀüÇØÁú, Ä®·Î¸® ¹× ¼öºÐÆòÇü Á¦Á¦ | Electrolytic, caloric and water-balance agents causing adverse effects in therapeutic use |
 |
Y546 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸° Àç¼öÈ¿°·ù | Oral rehydration salts causing adverse effects in therapeutic use |
 |
Y547 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¼®È¸È¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents affecting calcification causing adverse effects in therapeutic use |
 |
Y547 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºÎ°©»ó¼± È£¸£¸ó ¹× À¯µµÃ¼ | Parathyroid hormones and derivatives causing adverse effects in therapeutic use |
 |
Y547 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºñŸ¹Î D ±º | Vitamin D group causing adverse effects in therapeutic use |
 |
Y548 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¿ä»ê´ë»ç¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ | Agents affecting uric acid metabolism causing adverse effects in therapeutic use |
 |